دورية أكاديمية
أعرض في EDS

Clinical effectiveness of early treatment with paliperidone palmitate in schizophrenia: A retrospective real-world study in South Korea.

التفاصيل البيبلوغرافية
العنوان: Clinical effectiveness of early treatment with paliperidone palmitate in schizophrenia: A retrospective real-world study in South Korea.
المؤلفون: Shin W; Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea., Lee DH; Department of Physiology, CHA University School of Medicine, Seongnam, South Korea., Kim MK; Department of Psychiatry, CHA Ilsan Medical Center, CHA University School of Medicine, Goyang, South Korea., Lee SH; Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.; Department of Psychiatry, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea., Cho DY; Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea., Bang M; Department of Psychiatry, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea.
المصدر: Early intervention in psychiatry [Early Interv Psychiatry] 2021 Dec; Vol. 15 (6), pp. 1759-1767. Date of Electronic Publication: 2021 Jan 14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: Australia NLM ID: 101320027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1751-7893 (Electronic) Linking ISSN: 17517885 NLM ISO Abbreviation: Early Interv Psychiatry Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Carlton,VIC, Australia : Wiley-Blackwell
مواضيع طبية MeSH: Antipsychotic Agents*/adverse effects , Schizophrenia*/drug therapy, Delayed-Action Preparations/therapeutic use ; Humans ; Paliperidone Palmitate ; Retrospective Studies ; Treatment Outcome
مستخلص: Aim: Long-acting injectable antipsychotic agents (LAIs) including paliperidone palmitate (PP) have shown promising results in preventing relapse and rehospitalization in schizophrenia. This study aimed to ascertain the comparative real-world effectiveness between the early and late administration of PP and oral formulations of risperidone and paliperidone (ORPs) in patients experiencing a first episode or relapse of schizophrenia.
Methods: We identified patients with schizophrenia admitted to a psychiatric ward at least once and treated with ORPs or PP using the Korea National Insurance Claims Database. Patients were divided into three groups based on the clinical data: (1) patients treated with PP within 30 days of the initiation of treatment (early-PP), (2) patients treated with PP after 30 days of the initiation of therapy (late-PP) and (3) patients treated with only ORPs and not received PP (only-ORP). The primary outcomes were determined as psychiatric rehospitalization during the entire duration of treatment after the first discharge.
Results: A total of 3790 patients (1096 early-PP, 799 late-PP and 1895 only-ORP) were finally included in the analysis. The mean of number and total length of rehospitalization stays during the entire duration in early-PP group were significantly lower than those of late-PP group and only-ORP group (number: 2.32 stays/year, 3.24 stays/year and 4.23 stays/year, p < .001; total length: 50.34 days/year, 72.26 days/year and 105.14 days/year, p < .001).
Conclusions: Early treatment with PP was associated with a greater reduction in psychiatric rehospitalization during the treatment period than late treatment with PP and ORP in schizophrenia.
(© 2021 John Wiley & Sons Australia, Ltd.)
References: Alphs, L., Benson, C., Cheshire-Kinney, K., Lindenmayer, J. P., Mao, L., Rodriguez, S. C., & Starr, H. L. (2015). Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: A randomized, open-label, review board-blinded 15-month study. Journal of Clinical Psychiatry, 76, 554-561.
Alphs, L., Bossie, C. A., Sliwa, J. K., Fu, D. J., Ma, Y. W., & Hulihan, J. (2013). Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics. Neuropsychiatric Disease and Treatment, 9, 341-350.
Altamura, A. C., Sassella, F., Santini, A., Montresor, C., Fumagalli, S., & Mundo, E. (2003). Intramuscular preparations of antipsychotics: Uses and relevance in clinical practice. Drugs, 63, 493-512.
Bebbington, P. E., Angermeyer, M., Azorin, J. M., Marwaha, S., Marteau, F., & Toumi, M. (2009). Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Suppl, 119, 22-28.
Bratti, I. M., Kane, J. M., & Marder, S. R. (2007). Chronic restlessness with antipsychotics. American Journal of Psychiatry, 164, 1648-1654.
Brissos, S., Veguilla, M. R., Taylor, D., & Balanza-Martinez, V. (2014). The role of long-acting injectable antipsychotics in schizophrenia: A critical appraisal. Therapeutic Advances in Psychopharmacology, 4, 198-219.
Burch, E. A., Jr., & Ayd, F. J., Jr. (1983). Depot pipotiazine 1970-1982: A review. Journal of Clinical Psychiatry, 44, 242-247.
Chue, P., & Chue, J. (2012). A review of paliperidone palmitate. Expert Review of Neurotherapeutics, 12, 1383-1397.
Citrome, L., & Volavka, J. (2002). Optimal dosing of atypical antipsychotics in adults: A review of the current evidence. Harvard Review of Psychiatry, 10, 280-291.
Correll, C. U., Malhotra, A. K., Kaushik, S., McMeniman, M., & Kane, J. M. (2003). Early prediction of antipsychotic response in schizophrenia. American Journal of Psychiatry, 160, 2063-2065.
Daghistani, N., & Rey, J. A. (2016). Invega Trinza: The first four-times-a-year, long-acting injectable antipsychotic agent. P T, 41, 222-227.
De Risio, A., & Lang, A. P. (2014). History and therapeutic rationale of long acting antipsychotics. Current Clinical Pharmacology, 9, 39-52.
DeQuardo, J. R. (1998). Pharmacologic treatment of first-episode schizophrenia: Early intervention is key to outcome. Journal of Clinical Psychiatry, 59(Suppl 19), 9-17.
Faccincani, C., Mignolli, G., & Platt, S. (1990). Service utilisation, social support and psychiatric status in a cohort of patients with schizophrenic psychoses. A 7 year follow-up study. Schizophrenia Research, 3, 139-146.
Haro, J. M., Novick, D., Bertsch, J., Karagianis, J., Dossenbach, M., & Jones, P. B. (2011). Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study. British Journal of Psychiatry, 199, 194-201.
Jeong, H. S., & Shin, J. W. (2012). Trends in scale and structure of Korea's health expenditure over last three decades (1980-2009): Financing, functions and providers. Journal of Korean Medical Science, 27(Suppl), S13-S20.
Joshi, K., Lafeuille, M. H., Kamstra, R., Tiggelaar, S., Lefebvre, P., Kim, E., Yue, Y., & Tandon, N. (2018). Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits. Journal of Comparative Effectiveness Research, 7, 121-133.
Kane, J. M. (2014). Attitudinal barriers to prescribing LAI antipsychotics in the outpatient setting: Communicating with patients, families, and caregivers. Journal of Clinical Psychiatry, 75, e33.
Keith, S. J., Pani, L., Nick, B., Emsley, R., San, L., Turner, M., Conley, R., Scully, P., Chue, P. S., & Lachaux, B. (2004). Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatric Services, 55, 997-1005.
Kishimoto, T., Nitta, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2013). Long-acting injectable versus oral antipsychotics in schizophrenia: A systematic review and meta-analysis of mirror-image studies. Journal of Clinical Psychiatry, 74, 957-965.
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2014). Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. Schizophrenia Bulletin, 40, 192-213.
Koola, M. M. (2018). Anticholinergics to treat antipsychotic-induced extrapyramidal symptoms: Time to avoid this practice. Asian Journal of Psychiatry, 31, 100-101.
Leucht, C., Heres, S., Kane, J. M., Kissling, W., Davis, J. M., & Leucht, S. (2011). Oral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research, 127, 83-92.
Leucht, S., Barnes, T. R., Kissling, W., Engel, R. R., Correll, C., & Kane, J. M. (2003). Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. American Journal of Psychiatry, 160, 1209-1222.
Lieberman, J. A., Alvir, J. M., Koreen, A., Geisler, S., Chakos, M., Sheitman, B., & Woerner, M. (1996). Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology, 14, 13S-21S.
Marcus, S. C., Zummo, J., Pettit, A. R., Stoddard, J., & Doshi, J. A. (2015). Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. Journal of Managed Care & Specialty Pharmacy, 21, 754-768.
McEvoy, J. P., Byerly, M., Hamer, R. M., Dominik, R., Swartz, M. S., Rosenheck, R. A., Ray, N., Lamberti, J. S., Buckley, P. F., Wilkins, T. M., & Stroup, T. S. (2014). Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: A randomized clinical trial. JAMA, 311, 1978-1987.
Nasrallah, H. A. (2007). The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatrica Scandinavica, 115, 260-267.
Pandina, G., Lane, R., Gopal, S., Gassmann-Mayer, C., Hough, D., Remmerie, B., & Simpson, G. (2011). A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35, 218-226.
Prikryl, R., Prikrylova Kucerova, H., Vrzalova, M., & Ceskova, E. (2012). Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: A clinical perspective. Schizophrenia Research and Treatment, 2012, 764769.
Rabinowitz, J., Levine, S. Z., Barkai, O., & Davidov, O. (2009). Dropout rates in randomized clinical trials of antipsychotics: A meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophrenia Bulletin, 35, 775-788.
Robinson, D., Woerner, M. G., Alvir, J. M., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., & Lieberman, J. A. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241-247.
Robinson, D. G., Woerner, M. G., Alvir, J. M., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., Bilder, R., Goldman, R., & Lieberman, J. A. (1999). Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 156, 544-549.
Rueda-Vasquez, E. (1988). Outcome of treatment with haloperidol decanoate in a patient with schizophrenia, chronic undifferentiated type, and end stage renal disease. Military Medicine, 153, 595-596.
Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., Ambler, D., Puglia, M., Maloney, A. E., Michael, E., De Jong, S., Slifka, K., Noyes, N., Hlastala, S., Pierson, L., McNamara, N. K., Delporto-Bedoya, D., Anderson, R., Hamer, R. M., & Lieberman, J. A. (2008). Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. American Journal of Psychiatry, 165, 1420-1431.
Strauss, J. S., & Carpenter, W. T., Jr. (1978). The prognosis of schizophrenia: Rationale for a multidimensional concept. Schizophrenia Bulletin, 4, 56-67.
Tandon, R., & Jibson, M. D. (2003). Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology, 28(Suppl 1), 9-26.
Tarsy, D., Baldessarini, R. J., & Tarazi, F. I. (2002). Effects of newer antipsychotics on extrapyramidal function. CNS Drugs, 16, 23-45.
Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtala, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., & Taipale, H. (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry, 74, 686-693.
Vaillant, G. E. (1978). Prognosis and the course of schizophrenia. Schizophrenia Bulletin, 4, 20-24.
Verdoux, H., Pambrun, E., Tournier, M., Bezin, J., & Pariente, A. (2016). Antipsychotic long-acting injections: A community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation. Schizophrenia Research, 178, 58-63.
Weiden, P. J., & Olfson, M. (1995). Cost of relapse in schizophrenia. Schizophrenia Bulletin, 21, 419-429.
Weiden, P. J., Roma, R. S., Velligan, D. I., Alphs, L., DiChiara, M., & Davidson, B. (2015). The challenge of offering long-acting antipsychotic therapies: A preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. Journal of Clinical Psychiatry, 76, 684-690.
Wyatt, R. J., Damiani, L. M., & Henter, I. D. (1998). First-episode schizophrenia. Early intervention and medication discontinuation in the context of course and treatment. British Journal of Psychiatry. Supplement, 172, 77-83.
Zhang, F., Si, T., Chiou, C. F., Harris, A. W., Kim, C. Y., Jahagirdar, P., & Ascher, S. (2015). Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia. Neuropsychiatric Disease and Treatment, 11, 657-668.
فهرسة مساهمة: Keywords: nationwide cohort study; paliperidone palmitate; rehospitalization; schizophrenia
المشرفين على المادة: 0 (Antipsychotic Agents)
0 (Delayed-Action Preparations)
R8P8USM8FR (Paliperidone Palmitate)
تواريخ الأحداث: Date Created: 20210114 Date Completed: 20220310 Latest Revision: 20220311
رمز التحديث: 20231215
DOI: 10.1111/eip.13116
PMID: 33445224
قاعدة البيانات: MEDLINE
الوصف
تدمد:1751-7893
DOI:10.1111/eip.13116